Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106709 | 0.90 | PPARG (0.62) | PPARGCYP4F2CYP4A11ALDH1A1SMN1; SMN2 | |
| SCHEMBL5120118 | 0.89 | PPARG (0.51) | PPARGCYP4F2CYP4A11LMNAALDH1A1 | |
| SCHEMBL5119777 | 0.87 | PPARG (0.55) | PPARGLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL5108657 | 0.87 | PPARG (0.66) | PPARGLMNATSHR | |
| SCHEMBL5106765 | 0.86 | PPARG (0.57) | PPARGCYP4F2CYP4A11 | |
| SCHEMBL5120046 | 0.85 | PPARG (0.57) | PPARG | |
| SCHEMBL3218906 | 0.84 | PPARG (0.47) | PPARGLMNAALDH1A1 | |
| SCHEMBL3216029 | 0.83 | PPARG (0.78) | PPARG | |
| SCHEMBL3208041 | 0.83 | PPARG (0.53) | PPARGLMNAALDH1A1 | |
| SCHEMBL5114243 | 0.82 | PPARG (0.65) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | PPARG 52/4885CYP4F2 1398/4885CYP4A11 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.